ABSTRACT -The effects of histamine and its receptor antagonists on mouse bone marrow cells (MBMC) and MC3T3-E1 cells were studied to elucidate the precise molecular mechanisms underlying histamine activities in the respective cell types. The studied parameters were osteoclast differentiation and expressions of receptor activator of nuclear factor κB ligand (RANKL), histamine receptors (HR), and osteoblast differentiation markers. The osteoclastogenesis was assessed by TRAP-dye method. Expressions of RANKL, HR and the osteoblast differentiation markers were evaluated by RT-PCR analysis. In MBMC, 1 μM histamine doubled the number of osteoclast-like cells in a dose-dependent manner. Expressions of RANKL peaked at histamine concentrations of 1 μM and 0.1 μM in MBMC and MC3T3-E1, respectively. H 1 R antagonist, but not H 2 R antagonist, inhibited RANKL expressions induced by histamine in MC3T3-E1. Histamine induced expressions of cell differentiation markers in MC3T3-E1, but not in MBMC, under the conditions that RANKL expressions were induced by histamine in both types of cells. These results indicate the following: (1) Histamine induction of osteoclastogenesis is mediated by RANKL expressed via H 1 R, but not via H 2 R in mouse osteoblast-like cells; (2) and the major target of histamine action is the RANKL-RANK signaling pathway in osteocytes. This observation is consistent with the traditionally recognized histamine action of bone resorption at the osteoclast site.
INTRODUCTION
The immune system and bone metabolism have traditionally been considered two separate, unrelated fields of investigation. However, emerging evidence suggests that there are cross-regulatory mechanisms between the two systems. Immunocytes participate in differentiation processes of osteocytes by producing cytokines and differentiation factors at membrane sites. Furthermore, immune responses accompanying cellular defense mechanisms and abnormal activation of the immune system in autoimmune diseases directly influence bone metabolism (Takayanagi 2007) . Therefore, the study of immune regulation on the osteocytes is important to understand the clinical condition of autoimmune diseases and evaluate the effectiveness or safety of therapeutic drugs.
The osteoclast is differentiated from hematopoietic stem cells, and is the only cell that undergoes resorption in vivo. Macrophage colony-stimulation factor (M-CSF), a hematopoietic factor, transduces the signal for osteoclast differentiation through the differentiation factor, RANKL, which is expressed on the membranes of osteoblasts. RANKL is a cytokine that sustains osteoclast differentiation. The osteoclastogenesis signal is transmitted to osteoclast precursor cells by binding RANKL to its receptor, RANK, that is expressed in the osteoclast precursor cells (Yasuda et al., 1999) . Bone resorption factors such as 1α,25(OH) 2 vitamin D 3 , prostaglandin, parathyroid hormone and IL-6 have been shown to enhance the expression of RANKL (Kitazawa and Kitazawa, 2002; Tomita et al., 2002; Lee and Lorenzo, 2002) . On the other hand, an osteoclastogenesis inhibitor, osteoprotegerin (OPG), Correspondence: Koichi UENO (E-mail: kueno@p.chiba-u.ac.jp) has much higher affinity for RANKL than that of RANK, and thereby OPG is a strong competitive inhibitor of RANK (Yasuda et al., 1999) .
Histamine is a mediator of inflammatory reaction through histamine H 1 receptor (H 1 R) activation. Histamine has also been shown to increase cellular concentration of cAMP through activation of the histamine H 2 receptor (H 2 R) in a variety of target tissues, and thereby modulates many cellular functions. At present, however, there are considerable contradictory observations among the reports (Elenkov et al., 1998; Sirois et al., 2000; Nishibori et al., 2001) . Agents that affect the immune system often also affect bone metabolism, and histamine has been implicated in modulation of bone metabolism --particularly in bone resorption processes (Crisp et al., 1986; Hall and Schaueblin, 1994; Nakamura et al., 1996; Dobigny and Saffar, 1997) . However, the reports related to these subjects are scant, and the majority of such reports presents indirect observation of histamine activity in animal models, and lacks direct evidence at the molecular level. We reported previously that histamine induced osteoclast differentiation mainly through H 2 R activation in rat bone marrow cells (Yamaura et al., 2003) . Subsequently, Deyama et al. reported that histamine enhanced the expression of RANKL in MC3T3-E1 cells through H 1 R and H 3 R, but not through H 2 R (Deyama et al., 2002) . The discrepancy related to H 2 R and the lack of pertinent data concerning the precise roles of histamine in bone metabolism indicates a need for comparative studies on histamine actions at the molecular level in osteoblasts and osteoclasts. A mouse calvaria-derived osteoblast-like cell line, MC3T3-E1, and the primary culture of mouse bone marrow cells (MBMC) were used for the paradigms in the present study.
MATERIALS AND METHODS

Materials
Female C57BL/6 mice were obtained from Charles River Japan Inc. (Yokohama, Japan). Sodium hydrogen carbonate, sodium tartrate dihydrate and 10% formalin neutral buffer solution were purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan). ΦX174 RF DNA/Hae III Fragments and 1kb DNA Ladder were purchased from Invitrogen Co. USA) and αMEM was purchased from Gibco BRL (Grand Island, NY, USA). All other chemicals and reagents were purchased from Sigma Chemical Co (St. Louis, MO, USA). Histamine and mepyramine were solubilized in PBS, and cimetidine was dissolved in DMSO before use. Studies were conducted under the guidelines of the Care and Use of Laboratory Animals approved by The Japanese Pharmacological Society.
Cell culture
Mouse bone marrow cells (MBMC) obtained from the femur of C57BL/6 mice (6 weeks of age) were suspended in αMEM containing 10% FBS and grown for 24 hr, then the growth medium was changed to αMEM containing 15% FBS. After 24 hr of growth, the cells were suspended in the same medium to make the cell density 3.8 × 10 6 cells/mL. This cell suspension was used as a stock culture to seed the subcultures. After 24 hr from the time of seeding, the medium was changed to αMEM containing 15% FBS, and every 2 days thereafter the medium was changed to fresh medium of the same composition. MC3T3-E1 cells were suspended in αMEM containing 10% FBS at the cell density of 5 × 10 4 cells/mL, and this suspension was used as a stock culture for subcultures. All the cells were cultured at 37°C in a humidified atmosphere of 95% air and 5% CO 2 .
Treatment of cells
For the experiment concerning the effect of histamine on osteoclastogenesis in MBMC cultures, histamine was added to the medium on Day 3, and on Day 5 the medium was replaced with histamine-free medium. On Day 7, the cells were fixed with 10% formalin and stained for tartrate-resistant acid phosphatase (TRAP) in sodium acetate buffer (pH 5.0) containing 0.6 mg/mL of Fast Red Violet LB Salt, 0.1 mg/ mL naphthol AS-MX phosphate and 50 mM sodium tartrate. TRAP-positive cells containing two or more nuclei under the light microscope were counted as osteoclast-like cells.
For the experiment on the effect of histamine on RANKL expression in MBMC, the cells were stimulated by different concentrations of histamine for 48 hr from Day 3, and then the cells were harvested on Day 7 of the experiment. In the experiments with MC3T3-E1, cells were subcultured for 24 hr, treated with different concentrations of histamine for 6 hr, and then harvested immediately thereafter.
MC3T3-E1 cells subcultured for 24 hr were used to determine the steady state (the absence of histamine) expressions of histamine receptor subtypes, H 1 R and H 2 R in the osteoblast-like cells. For the effects of HR antagonists on histamine-mediated induction of RANKL in MC3T3-E1, the 24 hr old subcultured cells were stimulated with 0.1 μM histamine for 6 hr in the presence and in the absence of the antagonists.
Bone morphogenic protein (BMP2), alkaline phosphatase (ALP2), and core-binding factor alpha 1 (Cbfa1) were used for osteoblast differentiation markers (Yamaguchi et al., 2000; Wozney et al., 1998; Komori et al., 1997) . These served as markers of osteoblastic phenotypes and the state of metabolism of osteoblasts. MC3T3-E1 and MBMC were exposed to increasing concentrations of histamine for 6 hr and 48 hr, respectively. Expressions of all the specific mRNAs were assessed by the RT-PCR analysis method.
RT-PCR
Total mRNA was extracted from MBMC cultures and MC3T3-E1 cell cultures by following the protocol for RNeasy Mini Kit (QIAGEN, Hiliden, Germany). The reagents and protocol supplied with RNA PCR Kit (AMV) Ver. 2.1 (TaKaRa, Shiga, Japan) were used for RT-PCR. All necessary primers (Table 1) were purchased from Geneset Corp (Lajolla, CA, U.S.A.).
The RNA samples extracted from appropriate cells, in the amount of 2 μg, were reverse transcribed in the presence of 1 × RNA PCR buffer, 5 mM MgCl 2 , 1 mM dNTP, 125 nM Oligo dT-Adaptor Primer, 40 u RNase inhibitor, 10 u AMV Reverse Transcriptase XL, and 4 μL template RNA in the final volume of 40 μL.
The reverse transcription reaction was carried out at 45°C for 30 min, 99°C for 5 min, 5°C for 5 min, using Thermal Cycler (PTC-200 Peltier Thermal Cycler MJ Japan). The PCR was performed in 1 × RNA PCR buffer that contained 1 μM each of appropriate sense and antisense primers (Table 1 ), 1.5 mM MgCl 2 , 1 u TAKARA TaqTM, 5 μL of cDNAs obtained from the RT reaction in a final volume of 25 μL. After incubation at 95°C for 5 min, the mixture was subjected to a specific number of incubation cycles. One cycle consisted of 30 sec at 95°C, 30 sec at respective annealing temperatures, and 1 min at 72°C. After the appropriate number of cycles, the mixture was incubated for 5 min at 72°C before it was analyzed for the expression level by electrophoresis on 3% agarose gel. The bands were visualized by staining them with ethidium bromide. The sizes of the bands were confirmed by using 1 kb DNA Ladder or ΦX174 RF DNA/Hae III Fragments. The annealing cycle numbers and temperatures of H 1 R, H 2 R, RANKL, GAPDH, ALP2, BMP2, Cbfa1 were 25 cycles at 58°C, 30 cycles at 56°C, 30 cycles at 60°C, 20 cycles at 58°C, 28 cycles at 62°C, 30 cycles at 60°C, and 30 cycles at 52°C, respectively.
Analysis of PCR Products
The intensities of the resolved bands of PCR products on the agarose gel were measured by the use of Luminescent Image Analyzer LAS-1000 Plus (FUJIFILM, Tokyo, Japan). Relative Expression (RE) was calculated as follows: The measured intensity values of samples were normalized to the values of respective GAPDH (i.e. sample value/GAPDH value), and then normalized to appropriate control values as 100 %.
Other Pertinent Details
Additional procedures pertinent to particular experiments are described in the legends under the Figures in Results section.
RESULTS
Effect of Histamine on Osteoclast Differentiation in MBMC Cultures
Under the experimental conditions, the number of TRAP-positive multinucleated cells reached the highest level at the histamine concentration of 1 μM in a dose-dependent manner, and the number was over 2 times as many as that in the control culture (Fig.1A) .
Effects of H 1 R and H 2 R Antagonists (Mepyramine and Cimetidine) on Histamine-Induced Osteoclast Differentiation in MBMC Cultures
The H 1 R antagonist (mepyramine) tended to inhibit TRAP-positive multinucleated cell formation induced by 1 μM histamine to control level, and the H 2 R antagonist (cimetidine) significantly inhibited TRAP-positive multinucleated cell formation induced by 1 μM hitamine (Fig.1B) .
Histamine Mediated Stimulation of Osteoclast Differentiation Factor (RANKL) Expression
In MBMC cultures ( Fig.2A) , the expression of RANKL specific mRNA reached the maximum level at the histamine concentration of 1 μM as in the preceding experiment (Fig.1) where TRAP-positive multinucleated cells increased to maximum level at 1 μM histamine. In MC3T3-E1 cultures (Fig.2B) , the level of expression peaked at the histamine concentration of 0.1 μM.
Normal Steady State (i.e. in Absence of Histamine) Expressions of mRNA for H 1 R and H 2 R
The baseline expression levels of the 2 subtypes, H 1 R and H 2 R, were established in both MBMC (Fig.3A) and MC3T3-E1 (Fig.3B) .
Effects of H 1 R and H 2 R Antagonists (Mepyramine and Cimetidine) on Histamine-Induced Stimulation of RANKL Expression in MC3T3-E1
Under the experimental conditions, histamine stimulated RANKL expression by 21% (RE=121) in MC3T3-E1. The H 1 R antagonist (mepyramine) showed dose-dependent inhibitory effects, and at the antagonist concentration of 1 μM the histamine stimulation was reduced to 10% (RE=110). It was very little reduction in the RANKL expression by mepyramine, and the reproducibility of the experimental result was about fifty percent. In the case of the H 2 R antagonist (cimetidine) at the concentration of 1 μM the stimulatory effect of histamine remained the same (RE=121) (Fig. 4) .
Histamine-Mediated Expressions of Osteoblast Differentiation Markers in MC3T3-E1 and MBMC
The results contrast the histamine activities in osteoblasts to that in osteoclasts (Fig.5) . In MC3T3-E1 cultures (Fig.5A) , the expressions of all markers peaked at the histamine concentration of 0.1 μM. By comparison, in MBMC cultures (Fig.5B) , the exposure of the cells up to 1 μM histamine for 48 hr had no stimulatory effect on the expressions of the 3 markers.
DISCUSSION
The primary objective of the present study is to compare the actions of histamine in osteoblasts and in osteoclasts at the molecular level in order to clarify specific roles of histamine in the respective types of cells under conditions that sustain osteoclast differentiation. The first 3 experimental results ( Fig.1-Fig.3 ) set forth the conditions and the rationales for the subsequent experiments. These results confirm that histamine induces osteoclastogenesis (osteoclast differentiation) in a dose-dependent manner in MBMC that consist of precursor cells of both osteoblasts and osteoclasts (Fig.1) . Furthermore, histamine induces RANKL in both MBMC and MC3T3-E1 (Fig.2) . The present results from the MC3T3-E1 corroborate the previous report by Deyama et al. (2002) . These results support that histamine induces osteoclast differentiation via RANKL. MBMC needs more histamine than MC3T3-E1 cell to induce RANKL expression. We speculated that the degradation system of histamine might be increased in MBMC, because MBMC is mixture of haematopoietic stem cell and mesenchymal progenitor cell.
The result from the present study (Fig.4) showed that only the H 1 R antagonist inhibited histamineinduced RANKL expression in MC3T3-E1, confirming the report by Deyama and his colleagues (Deyama et al., 2002) . However, contrary to our earlier report concerning cimetidine in rat (Yamaura et al., 2003) and Vol. 32 No. 5 the present study in osteoclast formation from MBMC (Fig.1B) , the H 2 R antagonist did not inhibit the histamine induction of RANKL expression in the mousederived osteoblast-like cell line, MC3T3-E1. This result suggests that histamine promotes osteoclast formation by the H 1 R in osteoblast and H 2 R in osteoclast precursors. RANKL expression in bone cells is possible through the following 4 types of signal transduction pathways: (I) That mediated by 1α,25(OH) 2 vitamin D 3 (Yasuda et al., 1999) ; (II) That mediated by activation of protein kinase A (PKA) due to increased production of cAMP (Fu et al., 2002) ; (III) That mediated by signal transduction factor, gp130 (O'Brien et al., 1999) ; or (IV) That mediated by activation of protein kinase C (PKC) due to increased intracellular Ca 2+ concentration (Takami et al., 2000) . Both H 1 R and H 2 R are members of the G proteincoupled receptor super family. The primary signal transduction pathway used by H 1 R produces a functional response via Gq protein dependent activation of phospholypase C (PLC) and Ca 2+ mobilization. Therefore, the H 1 R induction of RANKL expression may be ascribed to the well-established signal transduction pathway that is mediated by activation of protein kinase C (PKC) due to increased intracellular Ca 2+ concentration (Takami et al., 2000) . H 2 R is a transmembranous receptor and it couples positively to adenylate cyclase via Gs protein. The coupling leads to formation of cAMP (Hill et al., 1997) , and thereby activates PKA. Another Gs protein dependent receptor, epinephrine β-receptor, also transmits signals by means of increased cAMP, and it induces osteoclast differentiation (Takeuchi et al., 2001 ). According to a recent report from aerospace research, gravity transduces cellular signals through the cAMP/PKA pathway (Kanematsu et al., 2002) . These observations suggest the likelihood that H 2 R influences RANKL expression through the cAMP/PKA pathway. Our result (Fig.4) indicates that in MC3T3-E1 systems, these possible pathways seem inoperative.
In general, bone resorption and bone formation maintain a close interrelationship. Furthermore, many agents that induce osteoclast differentiation are also known to exert their effects on osteoblasts as well. For these reasons MC3T3-E1 cells were used to study possible differentiation inducing effects of histamine on osteoblasts. Histamine induced the expression of differentiation markers − including the marker for osteoblast maturation − peaked at the histamine concentration of 0.1 μM, the same concentration at which expression of RANKL peaked. This result demonstrates that histamine stimulates the maturation and the differentiation of osteoblasts. By contrast, in MBMC that consisted of progenitors of both osteoblasts and osteoclasts, histamine induced RANKL expression, but had no effect on differentiation markers of osteoblasts. This result indicates that histamine promotes the binding of RANKL to RANK in osteoclast precursor cells (Yasuda et al., 1999) , and thereby induces maturation of osteoclasts that possess bone resorption capacity. In MBMC, however, histamine has no effect on osteoblasts other than induction of RANKL − i.e. no signs of osteoblast maturation or differentiation. The effects of histamine on bone marrow cells suggest that the effect of histamine on osteoclasts is greater than on osteoblasts, and the histamine effect on bone resorption outweighs its effect on bone formation. This proposition is consistent with the traditionally acknowledged osteolytic role of histamine at the osteoclast site. Therefore, it is considered that the drugs affect on histamine have some effects on osteoclastogenesis.
